{"id":"cetuximab-cisplatin-vinorelbine","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Neutropenia"},{"rate":"5-20%","effect":"Anemia"},{"rate":"5-20%","effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Cetuximab is a monoclonal antibody that binds to EGFR, preventing it from interacting with its ligands and thereby inhibiting tumor growth. Cisplatin is a platinum-based chemotherapy drug that forms platinum-DNA adducts, which interfere with DNA replication and transcription, leading to cell death. Vinorelbine is a vinca alkaloid that binds to tubulin, preventing microtubule formation and thereby inhibiting cell division.","oneSentence":"Cetuximab targets the epidermal growth factor receptor (EGFR), while cisplatin and vinorelbine work by interfering with DNA replication and cell division.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:05:24.112Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Head and neck cancer"}]},"trialDetails":[{"nctId":"NCT03529279","phase":"PHASE3","title":"CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-06-12","conditions":"Nasopharyngeal Carcinoma","enrollment":1324},{"nctId":"NCT00985855","phase":"PHASE2","title":"Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Institut de Cancérologie de la Loire","startDate":"2009-09","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":91},{"nctId":"NCT00842712","phase":"PHASE2","title":"Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2009-02","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":232},{"nctId":"NCT01109524","phase":"PHASE2","title":"Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-07","conditions":"Lung Neoplasms, Carcinoma, Cancer of the Lung","enrollment":72},{"nctId":"NCT01703910","phase":"PHASE2","title":"Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic","status":"COMPLETED","sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","startDate":"2012-11","conditions":"Adenocarcinoma of Colon, Adenocarcinoma of Rectum, Metastatic Disease","enrollment":29},{"nctId":"NCT00148798","phase":"PHASE3","title":"Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2004-10","conditions":"Non Small Cell Lung Cancer (NSCLC)","enrollment":1861},{"nctId":"NCT00820755","phase":"PHASE3","title":"Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2009-01","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":583},{"nctId":"NCT00522886","phase":"PHASE1","title":"Phase I Cetuximab and Concurrent Radio-chemotherapy","status":"COMPLETED","sponsor":"Maastricht Radiation Oncology","startDate":"2007-04","conditions":"Non-small Cell Lung Cancer","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"cetuximab + cisplatin + vinorelbine","genericName":"cetuximab + cisplatin + vinorelbine","companyName":"Merck KGaA, Darmstadt, Germany","companyId":"merck-kgaa-darmstadt-germany","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cetuximab targets the epidermal growth factor receptor (EGFR), while cisplatin and vinorelbine work by interfering with DNA replication and cell division. Used for Metastatic colorectal cancer, Head and neck cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}